Your browser doesn't support javascript.
loading
IκB kinase-α coordinates BRD4 and JAK/STAT signaling to subvert DNA damage-based anticancer therapy.
Pecharromán, Irene; Solé, Laura; Álvarez-Villanueva, Daniel; Lobo-Jarne, Teresa; Alonso-Marañón, Josune; Bertran, Joan; Guillén, Yolanda; Montoto, Ángela; Martínez-Iniesta, María; García-Hernández, Violeta; Giménez, Gemma; Salazar, Ramon; Santos, Cristina; Garrido, Marta; Borràs, Eva; Sabidó, Eduard; Bonfill-Teixidor, Ester; Iurlaro, Raffaella; Seoane, Joan; Villanueva, Alberto; Iglesias, Mar; Bigas, Anna; Espinosa, Lluís.
Affiliation
  • Pecharromán I; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
  • Solé L; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
  • Álvarez-Villanueva D; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
  • Lobo-Jarne T; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
  • Alonso-Marañón J; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
  • Bertran J; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
  • Guillén Y; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
  • Montoto Á; Faculty of Science and Technology, University of Vic - Central University of Catalonia, Vic, Spain.
  • Martínez-Iniesta M; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
  • García-Hernández V; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
  • Giménez G; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
  • Salazar R; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
  • Santos C; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
  • Garrido M; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Borràs E; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Sabidó E; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
  • Bonfill-Teixidor E; Proteomics Unit, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Iurlaro R; Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain.
  • Seoane J; Proteomics Unit, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Villanueva A; Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain.
  • Iglesias M; Vall d'Hebron Institute of Oncology (VHIO), CIBERONC, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Bigas A; Vall d'Hebron Institute of Oncology (VHIO), CIBERONC, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Espinosa L; Vall d'Hebron Institute of Oncology (VHIO), CIBERONC, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
EMBO J ; 42(21): e114719, 2023 11 02.
Article in En | MEDLINE | ID: mdl-37737566
Activation of the IκB kinase (IKK) complex has recurrently been linked to colorectal cancer (CRC) initiation and progression. However, identification of downstream effectors other than NF-κB has remained elusive. Here, analysis of IKK-dependent substrates in CRC cells after UV treatment revealed that phosphorylation of BRD4 by IKK-α is required for its chromatin-binding at target genes upon DNA damage. Moreover, IKK-α induces the NF-κB-dependent transcription of the cytokine LIF, leading to STAT3 activation, association with BRD4 and recruitment to specific target genes. IKK-α abrogation results in defective BRD4 and STAT3 functions and consequently irreparable DNA damage and apoptotic cell death upon different stimuli. Simultaneous inhibition of BRAF-dependent IKK-α activity, BRD4, and the JAK/STAT pathway enhanced the therapeutic potential of 5-fluorouracil combined with irinotecan in CRC cells and is curative in a chemotherapy-resistant xenograft model. Finally, coordinated expression of LIF and IKK-α is a poor prognosis marker for CRC patients. Our data uncover a functional link between IKK-α, BRD4, and JAK/STAT signaling with clinical relevance.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / I-kappa B Kinase Limits: Humans Language: En Journal: EMBO J Year: 2023 Document type: Article Affiliation country: Spain Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / I-kappa B Kinase Limits: Humans Language: En Journal: EMBO J Year: 2023 Document type: Article Affiliation country: Spain Country of publication: United kingdom